Epidemiological data for HHV-6 and HHV-8 in blood donor in Greece is poor. Their policy is in place to prevent tainted blood donations, something that makes sense to most normal people. In both populations antibody was strongly associated with sex, sexual orientation, years of sexual activity, number of lifetime sexual partners, and past infection with sexually transmitted diseases after other factors were controlled for. 8(4), 362–369 (2002). Cummins NW, Deziel PJ, Abraham RS, Razonable RR. However, the seroprevelance in blood donors in the U.K. The gays will feel useful, so it’s worth it!
Infect. Dis. 11(1), 20–27 (2009). It has been previously reported that the prevalence of HHV-8 in the general population in Greece is 7.6% and that the seropositivity for HHV-8 was associated with a history of endoscopic procedures and HBsAg positivity . Men who have had sex with men are also the largest group of blood donors to be found HIV positive. Semin. Respir.
Crit. In terms of HHV-6, the seroprevalence of HHV-6 in blood donors in Greece is unknown. Are we going to take that kind of a risk just to satisfy some sick idea about political correctness? Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J. The possibility of transfusion-related transmission of herpesviruses from healthy adult blood donors is moderately high for HHV-6, while it seems to be very low for HHV-8 .
And while certainly not all tainted blood transfusions come from blood donated from gay men, the point is that tainted blood transfusions do happen. 192(8), 1331–1339 (2005). Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S. A comparative study of herpes simplex infections in renal transplant and leukemic patients. But the fact, that no blood donor was positive for anti-HHV-8 IgG antibodies indicates that the risk for HHV-8 transmission with transfusion in Greece, if any, is negligible and does not warrant broad testing for HHV-8. This is continually made out to be an issue of discrimination when its actually an issue of public safety. Dis.
156(2), 280–287 (1987). Lowance D, Neumayer HH, Legendre CM et al. Further studies are needed, to clarify the potential risk of HHV-6 transmission from seropositive donors especially with high HHV-6 viral load but after the adoption of a common accredited detection method . Only the person who gets the tainted donation suffers. N. Engl. J.
Med. 340(19), 1462–1470 (1999). Zuckerman R, Wald A. Herpes simplex virus infections in solid organ transplant recipients. Am. J. Transplant 9(Suppl.
4), S104–S107 (2009). • This article summarizes the American Society of Transplantation’s recommendations for the prevention and treatment of herpes simplex virus infections in solid organ transplant recipients. Wald A, Huang ML, Carrell D, Selke S, Corey L. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J. Infect. Dis.
188(9), 1345–1351 (2003). Geel AL, Landman TS, Kal JA, van Doomum GJ, Weimar W. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant. Proc. 38(10), 3418–3419 (2006). Gourishankar S, McDermid JC, JhangriGS, Preiksaitis JK.
Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am. J. Transplant. 4(1), 108–115 (2004). Allen U, Preiksaitis J. Epstein–Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.
Am. J. Transplant. 9(Suppl. 4), S87–S96 (2009). • Summarizes the American Society of Transplantation’s recommendations for themanagement of Epstein–Barr virusinfections in solid organ transplantrecipients. Walker RC, Paya CV, Marshall WF et al.
Pretransplantation seronegative Epstein–Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J. Heart Lung Transplant. 14(2), 214–221 (1995). Merlo A, Turrini R, Dolcetti R, Zanovello P, Amadori A, Rosato A. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin.
Biol. Ther. 8(9), 1265–1294 (2008). Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect.
Dis. 184(11), 1461–1464 (2001). Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J. Clin. Microbiol.
40(3), 746–752 (2002). Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl.
4), S78–S86 (2009). • Summarizes the American Society of Transplantation’s recommendations for the prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365(9477), 2105–2115 (2005). Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Ann. Intern. Med. 143(12), 870–880 (2005). Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Am. J. Transplant. 4(4), 611–620 (2004). Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
Lancet 350(9093), 1729–1733 (1997). Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7), 779–795 (2010). • Summarizes the International Transplantation Society’s recommendations for the prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Am. J. Transplant. 10(5), 1228–1237 (2010). • Reports on a randomized clinical trial of 100 versus 200 days of valganciclovir prophylaxis in high-risk cytomegalovirus donor-positive/recipient-negative kidney transplant recipients. Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Am. J. Transplant. 9(5), 1205–1213 (2009). Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am.
J. Transplant. 7(9), 2106–2113 (2007). Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J. Infect.
Dis. 181(2), 717–720 (2000). Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am. J. Transplant.
9(Suppl. 4), S97–S100 (2009). • Summarizes the American Society of Transplantation’s recommendations for the management of human herpesvirus (HHV)-6, HHV-7 and HHV-8 in solid organ transplantrecipients. Bohl DL, Storch GA, Ryschkewitsch C et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am. J.
Transplant. 5(9), 2213–2221 (2005). Hirsch HH, Randhawa P. BK virus in solid organ transplant recipients. Am. J. Transplant.
9(Suppl. 4), S136–S146 (2009). • Summarizes the American Society of Transplantation’s recommendations for the prevention and treatment of BK virus infection in kidney transplant recipients. Levitsky J, Doucette K. Viral hepatitis in solid organ transplant recipients. Am. J.
Transplant. 9(Suppl. 4), S116–S130 (2009). • Summarizes the American Society of Transplantation’s recommendations for the prevention and treatment of viral hepatitisB and C in liver transplant recipients. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin.
Transpl. 17–37 (1998). Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27(1), 254–263 (1998). Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results.
Am. J. Transplant. 3(8), 999–1002 (2003). Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl.
7(6), 513–517 (2001). de Vera ME, Dvorchik I, Tom K et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am. J. Transplant. 6(12), 2983–2993 (2006).
Raza K, Ismailjee SB, Crespo M et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J. Heart Lung Transplant. 26(8), 862–864 (2007). Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening.
Am. J. Transplant. 3(8), 977–981 (2003). Ison MG, Michaels MG. RNA respiratory viral infections in solid organ transplant recipients. Am.
J. Transplant. 9(Suppl. 4), S166–S172 (2009). • Summarizes the American Society of Transplantation’s recommendations for the prevention and treatment of respiratory diseases due to RNA viruses in solid organ transplant recipients. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation.
Bone Marrow Transplant. 32(11), 1085–1088 (2003). Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect. Dis. 10(8), 521–526 (2010).
Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 119(4), 1277–1280 (2001). Ison MG, Szakaly P, Shapira M, Krivan G, Nist A, Dutkowski R. Oseltamivir prophylaxis significantly reduces the incidence of seasonal influenza infection in immunocompromised patients. Presented at: XI International Symposium on Respiratory Viral Infections. Bangkok, Thailand, 19–22 February 2009.
Groothuis JR, Simoes EA, Levin MJ et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med.
329(21), 1524–1530 (1993). Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J. Pediatr. Hematol. Oncol.
29(4), 227–232 (2007). Pelaez A, Lyon GM, Force SD et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J. Heart Lung Transplant. 28(1), 67–71 (2009). Glanville AR, Scott AI, Morton JM et al.
Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J. Heart Lung Transplant. 24(12), 2114–2119 (2005). Ison MG, Green M. Adenovirus in solid organ transplant recipients. Am.
J. Transplant 9(Suppl. 4), S161–S165 (2009). • Summarizes the American Society of Transplantation’s recommendations forthe prevention and treatment of adenovirus in solid organ transplantrecipients.